Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Debt Repayment

Cash used to repay borrowings during the period.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment dips below year-ago levels

Q1 FY2026 debt repayment of $111K (cash outflow) fell 97.3% year over year, behind the +639.8% change in trailing-twelve-month debt repayment. Sequentially, it fell 99.7% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Debt repayment amounted to 135.5% of revenue in FY2025, up 108.2 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -97.3% toward the trailing-twelve-month pace of +639.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$111K-99.7% QoQ
Last fiscal yearDec 2025
-$48.2M+2235.4% YoY
LTMMar 2026
-$44.26M+639.8% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.3%——
1 year+2235.4%——
3-year CAGR+3.3%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(48.2M) USD
Year-over-year change
-2235.4%

Debt Repayment vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 debt repayment of $44.26M is the largest of the 5 companies compared; the peer median is $93.02K.
  • Its year-over-year change of +639.8% is the highest of 2, against a peer median of -81.7%.
  • Debt repayment amounts to 119.1% of revenue for VRCA, versus a peer median of 8.7%.
VRCA Competitors Peer median
Debt Repayment for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$44.26M +639.8%+3.3%119.1%
QTTBQ32 Bio Inc.LTM Mar 2026$4.69M ——8.7%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$186.04K -81.7%-29.3%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding VRCA) $93.02K-81.7%-29.3%8.7%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Depreciation & Amortization472K718K836K1.27M429K
Deferred Income Tax66K0000
Stock-Based Compensation6.05M4.99M14.38M7.16M3.32M
Change in Working Capital(535K)(1.8M)9.86M2.03M(6.25M)
Accounts Receivables0(487K)(3.93M)4.34M(5.32M)
Inventory0487K000
Accounts Payables497K(338K)2.2M(568K)176K
Other Working Capital(1.03M)(1.46M)11.59M(1.74M)(1.11M)
Other Non-Cash Items1.44M1.93M3.35M5.19M2.76M
Operating Cash Flow(27.58M)(18.65M)(38.58M)(60.93M)(17.63M)
Capital Expenditures(883K)(302K)(362K)(27K)0
Acquisitions (Net)00000
Purchases of Investments(68.91M)(4.49M)000
Sales of Investments69M59.01M000
Other Investing Activities(201K)(180K)08K0
Investing Cash Flow(998K)54.04M(362K)(19K)0
Debt Repayment4.97M(43.75M)44.08M(2.06M)(48.2M)
Common Stock Issued28.12M26.9M30.3M39.64M50.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities558K(17K)(169K)155K(420K)
Financing Cash Flow33.65M(16.87M)74.21M37.73M1.45M
Effect of Forex Changes00000
Net Change in Cash5.07M18.52M35.27M(23.22M)(16.18M)
Free Cash Flow(28.47M)(18.95M)(38.94M)(60.95M)(17.63M)

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.